Select publications

Coleman RE et al. Intergroup Exemestane Study: 1-year results of the bone sub-protocol. San Antonio Breast Cancer Symposium 2004;Abstract 401.

Coombes RC et al. The Intergroup Exemestane Study: A randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen — Updated survival analysis. San Antonio Breast Cancer Symposium 2004;Abstract 3.

Howell A et al; ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-2. Abstract

Jakesz R et al. Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results from 3,123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial. San Antonio Breast Cancer Symposium 2004;Abstract 2.

Murray J et al. Letrozole and anastrozole: A pre-operative study of their effects on ER-positive breast cancers in postmenopausal women. San Antonio Breast Cancer Symposium 2004;Abstract 406.

Semiglazov VF et al. The relative efficacy of neoadjuvant endocrine therapy vs chemotherapy in postmenopausal women with ER-positive breast cancer. Presentation. ASCO 2004;Abstract 519.

Thürlimann B et al. Letrozole vs tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. BIG 1-98: A prospective randomized double-blind Phase III study. Breast 2005a;14(Suppl 1):3;S4.

Thürlimann BJ et al. BIG 1-98: Randomized double-blind phase III study to evaluate letrozole (L) vs tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptorpositive breast cancer. Presentation. ASCO 2005b;Abstract 511.